Hederacolchiside A1 Suppresses Autophagy by Inhibiting Cathepsin C and Reduces the Growth of Colon Cancer

Simple Summary Autophagy plays an important role in the survival of cancer cells under stress conditions that are poor for survival. Therefore, inhibition of autophagy is considered a novel approach to treating cancer. Hederacolchiside A1 (HA1) is known to have anticancer effects, but the relationship with autophagy has not been proven. In this study, we evaluated the effect of HA1 on the inhibition of autophagy and cell growth in colon cancer and presented its potential as a therapeutic agent. While autophagy degrades non-functional or unnecessary cellular components, producing materials for synthesizing cellular components, it can also provide energy for tumor development. Hederacolchiside A1 (HA1) derived from anemone raddeana has anticancer effects on several carcinomas by inducing apoptosis or exhibiting cytotoxicity, but the relationship with autophagy has not been studied. We investigated the association between HA1 and autophagy and evaluated its anticancer effect on colon cancer. HA1 induced accumulation of the autophagy-related markers LC3B and SQSTM1, with distinct vacuolar formation, unlike other autophagy inhibitors; the effects were similar to those of chloroquine. In addition, HA1 decreased the expression and proteolytic activity of lysosomal protein cathepsin C, reduced the growth of colon cancer cells in vitro, and inhibited tumor growth in vivo. It also reduced the expression of Ki-67 and cathepsin C in mouse tissues and reduced the growth of spheroids and organoids composed of cancer cells. Taken together, these results imply that HA1 regulates cell growth and autophagy and has potential as a promising therapeutic agent in colon cancer.

Automated summary

This study investigated the inhibitory effect of HA1 on cell growth and autophagy in colon cancer, suggesting its potential as a therapeutic agent.